Jeffrey Lawrence Winters

Jeffrey Lawrence Winters

Auto-generated profile, based on publicly available information

Jeffrey Lawrence Winters

Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
EBEvan M. Bloch
Evan M. Bloch
SSShmuel Shoham
Shmuel Shoham
ACArturo Casadevall
Arturo Casadevall
BSBruce S. Sachais
Bruce S. Sachais
BSBeth Shaz
Beth Shaz
ATAaron A.R. Tobian
Aaron A.R. Tobian
Severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS–CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., “convalescent”) plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource.

1 June 2013 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
JSJoseph Schwartz
Joseph Schwartz
JWJeffrey L. Winters
Jeffrey L. Winters
APAnand Padmanabhan
Anand Padmanabhan
RBRasheed A. Balogun
Rasheed A. Balogun
MDMeghan Delaney
Meghan Delaney
BSBeth H. Shaz
Beth H. Shaz

16 February 2012 in Blood
Verified
Journal Article
Open access
PDF file
PTPearl Toy
Pearl Toy
OGOgnjen Gajic
Ognjen Gajic
PBPeter Bacchetti
Peter Bacchetti
MLMark R. Looney
Mark R. Looney
MGMichael A. Gropper
Michael A. Gropper
FGfor the TRALI Study Group
for the TRALI Study Group
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. To determine TRALI incidence by prospective, active surveillance and to identify risk factors by a case-control study, 2 academic medical centers enrolled 89 cases and 164 transfused controls. Recipient risk factors identified by multivariate analysis were higher IL-8 levels, liver surgery, chronic alcohol abuse, shock, higher peak airway pressure while being mechanically ventilated, current smoking, and positive fluid balance. Transfusion risk factors were receipt of plasma or whole blood from female donors (odds ratio = 4.5, 95% confidence interval [CI], 1.85-11.2, P = .001), volume of HLA class II antibody with normalized background ratio more than 27.5 (OR = 1.92/100 mL, 95% CI, 1.08-3.4, P = .03), and volume of anti–human neutrophil antigen positive by granulocyte immunofluoresence test (OR = 1.71/100 mL, 95% CI, 1.18-2.5, P = .004). Little or no risk was associated with older red blood cell units, noncognate or weak cognate class II antibody, or class I antibody. Reduced transfusion of plasma from female donors was concurrent with reduced TRALI incidence: 2.57 (95% CI, 1.72-3.86) in 2006 versus 0.81 (95% CI, 0.44-1.49) in 2009 per 10 000 transfused units (P = .002). The identified risk factors provide potential targets for reducing residual TRALI.

1 January 2010 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
ZSZbigniew M. Szczepiorkowski
Zbigniew M. Szczepiorkowski
JWJeffrey L. Winters
Jeffrey L. Winters
NBNicholas Bandarenko
Nicholas Bandarenko
HKHaewon C. Kim
Haewon C. Kim
MLMichael L. Linenberger
Michael L. Linenberger
BSBeth H. Shaz
Beth H. Shaz

19 January 2006 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MSM D Stegall
M D Stegall
JGJ. Gloor
J. Gloor
JWJ.L. Winters
J.L. Winters
SMS.B. Moore
S.B. Moore
SDS. DeGoey
S. DeGoey
Several protocols allow for the successful transplantation of sensitized renal allograft recipients, yet no one best method has emerged. The aim of the current study was to compare the efficacy of high‐dose IVIG with two different plasmapheresis (PP)‐based regimens in kidney transplant recipients with high levels of donor specific alloantibody (DSA) defined as a positive T‐cell cytotoxicity crossmatch. With the primary goal of achieving a negative crossmatch, we employed three protocols sequentially between April 2000 and May 2005: (i) PP, low‐dose IVIG, anti‐CD20 antibody (n = 32); (ii) high‐dose IVIG (n = 13); and (iii) PP, low‐dose IVIG, anti‐CD20 antibody and pre‐transplant Thymoglobulin combined with post‐transplant DSA monitoring (n = 16). IVIG decreased DSA activity in all treated patient, yet only 38% (5/13) achieved a negative crossmatch. In contrast, a negative crossmatch was achieved in 84% in PP group and 88% in the PP/monitoring group (p < 0.01 vs. IVIG). Even with a negative crossmatch, the rejection rates were 80% (IVIG), 37% (PP) and 29% (PP/monitoring), respectively, (p < 0.05 IVIG vs. PP). We conclude that multiple PP treatments leads to more reproducible desensitization and lower humoral rejection rates than a single high‐dose of IVIG, but that no regimen was completely effective in preventing humoral rejection.

1 September 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MJMichael Joyner
Michael Joyner
KBKatelyn Ann Bruno
Katelyn Ann Bruno
SKStephen A. Klassen
Stephen A. Klassen
KKKatie L Kunze
Katie L Kunze
PJPatrick Johnson
Patrick Johnson
RWR. Scott Wright
R. Scott Wright